Congressional oversight of Part D
Executive Summary
Drug manufacturer rebates will be part of the House Energy and Commerce Committee's oversight agenda as the panel assesses the Medicare Part D drug program. Other Part D topics for review include the annual reassignment of individuals who are dually eligible for both Medicare and Medicaid, the effectiveness of private plans' administration of the Part D program and CMS oversight of the plans